C-reactive protein like marker of the inflammation associated to the metabolic syndrome. Must be treated the inflammation?

Authors

  • Raúl Orlando Calderín Bouza Hospital Clínico Quirúrgico "Hermanos Ameijeiras". La Habana, Cuba.
  • Miguel Ángel Yanes Quesada Hospital Clínico Quirúrgico "Hermanos Ameijeiras". La Habana, Cuba.
  • Marelis Yanes Quesada Hospital Clínico Quirúrgico "Hermanos Ameijeiras". La Habana, Cuba.
  • Jorge Luís León Álvarez Hospital Clínico Quirúrgico "Hermanos Ameijeiras". La Habana, Cuba.

Keywords:

inflammation, metabolic syndrome, C-reactive protein

Abstract

The insulin resistance and the chronic inflammatory state are the main cause in the pathogenia of the metabolic syndrome. C-reactive protein is a potent marker of inflammation and insulin resistance. In addition, high levels of insulin resistance can predict in the patient with metabolic syndrome, with or without prediabetes (impaired fasting glucose, impaired glucose tolerance), the development of type 2 diabetes mellitus and cardiovascular illness. For this reason we recommend to include C-reactive protein in the assessment of patients with metabolic syndrome; besides, beginning treatment once the inflammatory state is diagnosed, with medication that reduce the levels of reactive C protein and at same time improve sensibility to the insulin, as well as recommended changes in lifestyle.

Downloads

Download data is not yet available.

Author Biography

Raúl Orlando Calderín Bouza, Hospital Clínico Quirúrgico "Hermanos Ameijeiras". La Habana, Cuba.

Medicina Interna. Profesor Auxiliar

Hospital Clinico Quirúrgico “Hermanos Ameijeiras”. San Lázaro 701, e/ Belascoaín y Márqués González. Centro Habana 10300. La Habana, Cuba. Correo electrónico: rcb@infomed.sld.cu

References

1. Gorjão R, Kenji Takahashi H, An Pan J, Massao Hirabara S. Molecular mechanisms involved in inflammation and insulin resistance in chronic diseases and possible interventions. J Biomed Biotechnol. 2013;12:11-55.

2. Arroyo Espliguero R, Avanzas P, Kaski JC. Enfermedad cardiovascular aterosclerótica: la utilidad de la proteína C reactiva en la identificación de la placa vulnerable y del paciente vulnerable. Rev Esp Cardiol. 2004;57:375-8.

3. Smith S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med. 2005;12:75-80.

4. Ford Es, Li C, Zhao G. Prevalence and correlates of metabolic síndrome base don harmonious definition among adults in the US. J Diabetes. 2010;2:180-93.

5. Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Syndrome: mediators, antecedents, and measurement. Diabetes Care. 2006;29:1700-6.

6. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol. 2006;97:3-11.

7. Oda E. Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol. 2012; 49:89-95.

8. Saltar N, Gaw A, Sherbakova O, Ford I, O’Relly DS, Haffner SM, et al. Metabolic syndrome with and without C- reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation. 2003;108:114-9.

9. Body V, Sanchis J. La proteína C reactiva en el síndrome coronario agudo. Una mirada atrás para seguir avanzando. Rev Esp Cardiol. 2006;59:418-20.

10. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;16:1793-801.

11. Corwin EJ, McCoy CS, Whetzel CA, Ceballos RM, Klein LC. Risk indicators of metabolic syndrome in young adults: a preliminary investigation on the influence of tobacco smoke exposure and gender. Heart Lung. 2006;35:119-29.

12. Blomgarden ZT. Insulin resistance: causes and consequences. Int Rev Neurobiol. 2005;65:1-24.

13. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the women's health study: a randomized controlled trial. JAMA. 2005;294:47-55.

14. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, et al. Relationship between C reactive protein and subclinical atherosclerosis: the Dallas heart study. Circulation. 2006;113: 38-43.

15. L'ltalien G, Ford I, Norrie J, LaPuerta P, Ehreth J, Jackson J, et al. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the west of Scotland coronary prevention study (WOSCOPS). Am J Cardiol. 2000;85:720-4.

16. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116:1813-22.

17. Reaven G. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation. 2005;112:3030-2.

18. Steinberg GR. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle. 2007;6:888-94.

19. Khera A, McGüire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005; 46:464-9.

20. Mitchell BD, Zaccaro D, Wagenknecht LE, Scherzinger AL, Bergman RN, Haffner SM, et al. Insulin sensitivity, body fat distribution, and family diabetes history: the IRAS family study. Obes Res. 2004;12:831-9.

21. Blommgarden ZT. Aspects of type 2 diabetes and related insulin-resistant states. Diabetes Care. 2006;29:732-40.

22. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest. 2006; 116:1756-60.

23. Bhattacharya S, Dey D, Roy SS. Molecular mechanism of insulin resistance. J Biosci. 2007; 32:405-13.

24. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the centers for disease control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;19:223-56.

25. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003; 107:499-511.

26. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of obesity. Circulation. 2009;120:1640-5.

27. DeFronzo RA. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler. 2006;7(Suppl):11-5.

28. Blommgarden ZT. Inflammation, atherosclerosis, and aspects of insulin action. Diabetes Care. 2005;28:2312-9.

29. Shadid S, Stehower CD, Jensen MD. Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab. 2006;27:1123-9.

30. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin survival study (4S) and the air force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93:136-41.

31. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5:295-309.

32. Kim SH, Abbasi F, Chu JW, McLaughlin TL, Lamendola C, Polonsky KS, et al.Rosiglitazone reduces glucose-stimulated insulin secretion rate and Increases insulin clearance in non-diabetic, insulin-resistant individuals. Diabetes 2005; 54:2447-52.

33. Smith SC, Anderson JL, Cannon RO, Fadl YY, Koenig W, Libby P, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation. 2004;110:e550-3.

34. Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM. Implications from the air force/Texas coronary atherosclerosis prevention study for the adult treatment panel III guidelines. Am J Cardiol. 2005;96:1674-80.

35. Abdullah SM, Khera A, Leonard D, Das SR, Canham RM, Kamath SA. Sex differences in the association between leptin and CRP: results from the Dallas heart study. Atherosclerosis. 2006;30:203-45.

36. American diabetes association. Position statement. Standards of medical care in diabetes. Diabetes Care. 2014;37:s14-80.

Downloads

Published

2015-05-25

How to Cite

1.
Calderín Bouza RO, Yanes Quesada M Ángel, Yanes Quesada M, León Álvarez JL. C-reactive protein like marker of the inflammation associated to the metabolic syndrome. Must be treated the inflammation?. Acta Médica [Internet]. 2015 May 25 [cited 2025 May 22];16(1). Available from: https://revactamedica.sld.cu/index.php/act/article/view/856

Issue

Vol. 16 No. 1 (2015): Enero-Junio

Section

Artículo de opinión

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).